ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SYNC Syncona Limited

126.40
0.40 (0.32%)
Last Updated: 15:00:25
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.40 0.32% 126.40 126.00 126.40 127.00 124.00 124.00 115,523 15:00:25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Trust,ex Ed,religious,charty -39.79M -56.02M -0.0840 -14.88 833.42M

Syncona Limited Dividend Announcement (1357C)

13/06/2019 2:27pm

UK Regulatory


Syncona (LSE:SYNC)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Syncona Charts.

TIDMSYNC

RNS Number : 1357C

Syncona Limited

13 June 2019

13 June 2019

Syncona Limited

Dividend Announcement

The Directors of Syncona Limited have declared that a scrip dividend for the year ended 31 March 2019 of 2.3 pence per ordinary share will be paid on 29 July 2019 to those shareholders on the register of members of the Company as at 21 June 2019* (ex-dividend date 20 June 2019).

* note that this represents a correction from the record date of 20 June 2019 previously published at 07:00 on 13 June 2019 via RNS Number 0375C.

[ENDS]

Enquiries

Syncona Ltd

Annabel Clay / Siobhan Weaver

Tel: +44 (0) 20 3981 7940

FTI Consulting

Brett Pollard / Ben Atwell / Natalie Garland-Collins

Tel: +44 (0) 20 3727 1000

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

Copies of this press release, a company results presentation, and other corporate information can be found on the company website at: www.synconaltd.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DIVBXGDLUDBBGCX

(END) Dow Jones Newswires

June 13, 2019 09:27 ET (13:27 GMT)

1 Year Syncona Chart

1 Year Syncona Chart

1 Month Syncona Chart

1 Month Syncona Chart

Your Recent History

Delayed Upgrade Clock